Outcomes Based Arrangements in Biopharma
- By Lilian Zhang, Tory Wolff, and Jason Brauner
- Biopharma ,
- Payers ,
- Institutional
Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
